UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

PURPOSE: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133 have been posited as possible stem cell like cancer cells (SCLCC), a potential source of drug r...

Full description

Bibliographic Details
Main Authors: Adele P. Williams, Evan F. Garner, Laura L. Stafman, Jamie M. Aye, Colin H. Quinn, Raoud Marayati, Jerry E. Stewart, Venkatram R. Atigadda, Elizabeth Mroczek-Musulman, Blake P. Moore, Elizabeth A. Beierle, Gregory K. Friedman
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319302670

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319302670

Similar Items